ResMed Inc. — 7.7/10 — $224.09

ResMed is a global medical device and SaaS company focused on sleep apnea, COPD, and out-of-hospital healthcare IT. The company holds approximately 48% global CPAP market share and operates in a near-duopoly with Fisher & Paykel Healthcare since Philips Respironics exited the US CPAP market following its 2021 recall. The quality gate PASSES on all three criteria -- oligopoly PASS (near-duopoly), FCF $1.79B LTM (100%+ NI conversion, 5.5% yield), and management hit rate of 9/12 promises met or exceeded with zero misses. No capitalization cap.

The investment case centers on a near-duopoly medtech compounder at a deeply discounted valuation with the GLP-1 narrative definitively wrong. CEO Mick Farrell on Q2 FY26: "The thesis that this could be a headwind is completely gone. It is a tailwind." ResMed now has 1.95M patient claims proving GLP-1 plus CPAP patients are 10-11% more likely to start therapy and 6.2% more likely to resupply at 3 years. The total addressable market is massive -- approximately 936M to 1B people globally with OSA, with ~80% undiagnosed. Farrell describes this as "mile 1 of the marathon."

Financial trends show exceptional margin expansion and FCF transformation. Revenue growth is decelerating from +18% (FY23 Philips peak) to ~10-11% currently, but mask revenue is re-accelerating to +16%. The margin story is the standout: gross margin has expanded from a 55.8% trough to 62.3% non-GAAP (+580bps), with operating margin at 36.3% non-GAAP -- best-in-class medtech. FCF has transformed from $216M in FY22 to $1.79B LTM. Non-GAAP EPS is growing +15-24% driven by operating leverage.

The valuation is the strongest contrarian signal. At 19x forward P/E, ResMed trades at a ~27% discount to its own 5-year median of ~30x and roughly half the multiple of Fisher & Paykel (~39x). PEG ratio is 0.86. Short interest is elevated at 8.2%. December 2025 downgrades from Baird and Stifel anchored negative sentiment, but fundamentals have only improved since. The SaaS segment (~6% growth, decelerated from high-teens) is the weak spot, with management expecting HSD reacceleration in H2 FY26.

RMD receives a composite score of 7.7/10, reflecting a near-duopoly medtech compounder with exceptional margin expansion and the strongest contrarian signal in the screener -- the GLP-1 narrative has been definitively disproven by 1.95M patient claims data, yet the market continues to discount the stock.

Bull case ($300, +34%): GLP-1 tailwind recognition drives multiple re-rating from 19x toward the 5-year median of ~30x. Gross margin expansion continues its 300+bps/yr trajectory through 2030 as manufacturing efficiencies and mix shift to higher-margin masks compound. Mask revenue sustains +16% growth as the PCP channel education initiative (60K+ CME completions) drives new patient starts. SaaS reaccelerates to HSD in H2 FY26 as promised. Philips remains out of the US market, extending the near-duopoly. FCF approaches $2B+ and buybacks continue scaling ($175M/qtr).

Base case ($220-250): Revenue growth stabilizes at 10-11% with masks driving the portfolio. Margin expansion continues but at a decelerating pace as the easy gains from the 55.8% trough are realized. SaaS growth remains at 5-7%, below the prior high-teens trajectory. P/E gradually expands from 19x toward 22-24x as the GLP-1 overhang fades. Philips timeline remains unclear. FCF sustains above $1.7B with consistent capital return.

Bear case ($184, -18%): Philips announces US CPAP re-entry, compressing the duopoly premium and pressuring pricing. Oral GLP-1 formulations narrow the mild OSA addressable market over time. SaaS growth fails to reaccelerate and becomes a drag on the multiple. Key-man risk materializes with Farrell departure. Multiple contracts to 15-16x forward P/E.

Bottom line: ResMed is the best risk/reward in the screener given the quality of the business at a cheap valuation. A near-duopoly medtech franchise with 62.3% gross margins, $1.79B FCF, and 15-24% EPS growth trading at 19x forward P/E (PEG 0.86) because the market spent 2+ years pricing in a GLP-1 headwind that the data now definitively refutes. The 8/10 contrarian sentiment score is the strongest signal -- this is genuine management contrarianism backed by 1.95M patient claims, not a hope trade.

Key catalysts and monitoring points:

• GLP-1 narrative recognition: The 1.95M patient claims dataset proving GLP-1 is a tailwind (10-11% more likely to start CPAP, 6.2% more likely to resupply at 3yr) is the single most important catalyst. Track whether sell-side models begin incorporating this as a positive rather than a risk factor.
• SaaS reacceleration: Growth decelerated to ~6% from high-teens. Management expects HSD reacceleration in H2 FY26. This is the key promise yet to be delivered -- failure would pressure the multiple and raise questions about the SaaS platform thesis.
• Philips US re-entry timing: CEO Farrell says he "does not know" when Philips will return to US CPAP. Any announcement from Philips regarding FDA clearance or US re-launch timing would be a negative catalyst. Monitor Philips earnings calls and FDA filings.
• Gross margin trajectory: 62.3% non-GAAP with management guiding runway through 2030. Track whether the 300+bps/yr expansion pace sustains -- this is the primary earnings driver beyond revenue growth.
• Mask revenue growth: Re-accelerating to +16%, driven by AirFit F40 adoption and PCP channel expansion (60K+ CME completions). Masks are higher margin and recurring -- sustained double-digit growth here is critical to the margin expansion story.
• Buyback trajectory: Scaled from $50M to $175M per quarter. At $224, management clearly sees value. Monitor whether pace sustains or accelerates -- a signal of internal conviction on the GLP-1 tailwind thesis.
• Competitive bidding exclusion: Removal of CPAP from competitive bidding would eliminate a longstanding Medicare reimbursement overhang. Track CMS policy updates.
• Short interest: Currently 8.2%. A short squeeze catalyst exists if GLP-1 tailwind data forces covering. Monitor monthly changes.
• Next earnings: ~Late April/May 2026 (Q3 FY26). Key focus on SaaS reacceleration evidence, mask growth sustainability, margin trajectory, and updated GLP-1 claims data.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Accumulate -- ResMed is a near-duopoly medtech compounder trading at a 27% discount to its own historical multiple because the market spent 2+ years pricing in a GLP-1 headwind that 1.95M patient claims now definitively disprove. The stock at $224.09 is ~24% below its 52-week high of $293.81, below both the 50-day ($246.91) and 200-day ($258.01) moving averages, reflecting persistent negative sentiment that has diverged from improving fundamentals.

The quality of the franchise is exceptional. This is a ~48% global CPAP near-duopoly with 62.3% gross margins, 36.3% operating margins (best-in-class medtech), $1.79B FCF at 5.5% yield, and a massive undiagnosed TAM (~80% of ~1B OSA patients untreated). Management has a 9/12 hit rate with zero misses, has raised gross margin guidance twice, and is backing conviction with $175M/qtr buybacks and +13% dividend growth. The digital moat (6M+ connected devices, 11M myAir users) creates switching costs that no competitor can replicate at scale.

What would change the recommendation up: (1) SaaS reaccelerates to HSD as guided for H2 FY26, removing the last fundamental question mark. (2) Philips confirms extended absence from US CPAP, solidifying the duopoly for 2+ more years. (3) Multiple re-rates from 19x toward 25x+ as GLP-1 tailwind becomes consensus. (4) Competitive bidding exclusion removes the Medicare reimbursement overhang. (5) Oral GLP-1 data confirms similar CPAP adherence boost as injectable.

What would change the recommendation down: (1) Philips announces imminent US CPAP re-entry with FDA clearance. (2) SaaS growth fails to reaccelerate and declines further below 5%. (3) Oral GLP-1 data shows reduced need for CPAP in mild OSA patients, narrowing the addressable market. (4) Key-man risk: Farrell departure without a clear succession plan. (5) Gross margin expansion stalls or reverses due to competitive pricing pressure.